ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / MNPR
INDP (42) PHAT (33) FTH (28) EOLS (26) ⌘ Pro Terminal →

Monopar Therapeutics Inc. (MNPR) — RQD Stock Rating Cockpit

$66.28 -5.74% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $65.47

Monopar Therapeutics Inc. (MNPR) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $472.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MNPR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MNPR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Monopar Therapeutics Inc. (NASDAQ: MNPR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $66.28 (-5.74% 1D, market cap $472.0M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, MNPR ranks #883 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MNPR compare to INDP and PHAT in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MNPR carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -17.4%. By comparison, INDP (Indaptus Therapeutics Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $474.6M) and PHAT (Phathom Pharmaceuticals Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $466.6M). Among the 5-stock peer group, MNPR leads on earnings multiple (N/A) while MNPR leads on capital efficiency (-17.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MNPR?
▼

Per MNPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001645469), Monopar Therapeutics Inc. generated $46.8M in revenue (+3.4% YoY), -$13.7M in net income, and -$12.2M in free cash flow against $140.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $65.47 (-1.22%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510027
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (4)Whales (4)SEC (10)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-14% Base Target
$131 Bull$57 Base$44 Bear
📬 FREE MNPR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MNPR)Realized 20D OHLCV Swing Band: ±10.3%
Deterministic 5-Pillar Attribution (27/100 Composite)
🔍 WHY MNPR SCORES 27/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (37% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+6/20 pts (22% of score)

FRED Regime × Technicals: 22% of 52W Range • RSI-14 at 35.2 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
35
Grade E$72.08+3% Next Q
Q2 (-2Q)
32
Grade E$74.23-3.2% Next Q
Q3 (-1Q)
30
Grade E$71.84-7.7% Next Q
Current
27
Grade E$66.28-10.3% Hist 90D α
Trajectory: E (35) → E (27)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MNPR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MNPR currently carries a cautious 27/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($89.54) and Max Pain ($69.59) forces dealer call-delta covering toward $131.06.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MNPR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MNPR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 27%NO 73%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
35.230 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE22% OF RANGE
L: $50$66.28H: $125
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 7 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 16 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on MNPR

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (20)

-17.4% ROIC with 42.0% gross margin and -2.53% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (22)

7/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like MNPR
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MNPR)

  • ✓Walkthrough of MNPR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
MNPR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +21.30%▼ SUPPORT BREAKDOWN
2026-11-03O $71.91H $71.91L $66.28C $66.28VOL 197.8K
RES: $127.0SUP: $70.26SMA50: $89.54SMA200: $77.25
$129.9$108.7$87.55$66.36$45.17RES $127.0SUP $70.26$66.282026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MNPR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MNPR Butterfly Map → + Track MNPR →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +3.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MNPR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MNPR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MNPR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MNPR)

Health Care Rank #883 of 1015 ⚔️ INDP vs MNPR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MNPR vs. INDP, PHAT, FTH, EOLS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Monopar Therapeutics Inc. (MNPR) ranks #883 by composite RQD confidence (27/100, grade E) and #454 by equity capitalization ($472.0M). Within this direct 5-issuer industry benchmark cohort, MNPR leads on earnings valuation at N/A trailing P/E, while MNPR leads on capital efficiency and profitability with -17.4% ROIC and — gross margin. INDP currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with MNPR at 27/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MNPR ACTIVE
Monopar Therapeutics Inc.
E 27/100 — — -17.4% -5.74% $472.0M Benchmark Subject
INDP
Indaptus Therapeutics Inc.
D- 42/100 — — -35.0% +13.27% $474.6M /indp-vs-mnpr →
PHAT
Phathom Pharmaceuticals Inc.
E 33/100 — 87.1% -35.0% +3.05% $466.6M /phat-vs-mnpr →
FTH
Faeth Therapeutics Inc.
E 28/100 — — -35.0% +2.89% $483.0M /fth-vs-mnpr →
EOLS
Evolus Inc.
E 26/100 — 66.3% -35.0% -2.58% $485.5M /eols-vs-mnpr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001645469 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Monopar Therapeutics Inc. (MNPR) reported GAAP revenue of $46.8M (+3.4% vs. FY2024 revenue of $45.3M , and +89.2% cumulative change since FY2023) , GAAP net income of -$13.7M, operating cash flow of -$12.2M, and free cash flow of -$12.2M (-90.5% YoY). On the balance sheet, MNPR closed FY2025 with $140.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $46.8M -$13.7M -$12.2M -$12.2M $140.7M —
FY2024 (FY) 2024-12-31 $45.3M -$15.6M -$6.4M -$6.4M $60.3M —
FY2023 (FY) 2023-12-31 $24.7M -$8.4M -$7.9M -$7.9M — —

3. MNPR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MNPR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Monopar Therapeutics Inc. (NASDAQ: MNPR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $66.28 (-5.74% 1D, market cap $472.0M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, MNPR ranks #883 in composite RQD confidence.

How does MNPR compare to INDP and PHAT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MNPR carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -17.4%. By comparison, INDP (Indaptus Therapeutics Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $474.6M) and PHAT (Phathom Pharmaceuticals Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $466.6M). Among the 5-stock peer group, MNPR leads on earnings multiple (N/A) while MNPR leads on capital efficiency (-17.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MNPR?

Per MNPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001645469), Monopar Therapeutics Inc. generated $46.8M in revenue (+3.4% YoY), -$13.7M in net income, and -$12.2M in free cash flow against $140.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MNPR trading relative to its 50-day, 200-day, and 52-week technical levels?

MNPR last traded at $66.28 (-5.74% on volume of 218,916 shares), positioning the stock -25.98% below its 50-day simple moving average ($89.54) and -14.20% below its 200-day simple moving average ($77.25). Across its 52-week range of $50.07 to $124.82, MNPR sits at the 21.7% percentile with a 14-day RSI of 35.2 (NEUTRAL RANGE) and an implied next-earnings move of ±10.3% ($59.45 to $73.11).

Direct Sub-Reports: MNPR RQD Cockpit MNPR 12M Forecast MNPR Earnings & Move MNPR Dividends & DRIP MNPR Insiders & 13F MNPR Whale Options MNPR Profit Sankey MNPR News & Why
ROARABLE RATING BRIEF • RQD 27/100 (E) ✓ SEC XBRL & RQD VERIFIED

MNPR — Monopar Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Monopar Therapeutics Inc. (MNPR) earns a live Roarable RQD composite score of 27/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $66.28 (-5.74% 1D, market capitalization $472.0M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -17.4%, gross margin of —, operating margin of —, and free cash flow yield of -2.53%.
  • Whale 13F & Options Flow (4/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Monopar Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..5B. —: specific product descriptions, customer base, and revenue model. The FY 2025 and FY 2024 filings report revenue of — in each period, which the financials section indicates the company does not currently generate reported revenue.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Monopar Therapeutics Inc. (MNPR) reported $46.8M in annual revenue (up from $45.3M in FY2024, +3.4% YoY) and -$13.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($24.7M revenue, -$8.4M net income) through FY2025, MNPR scaled operating cash flow to -$12.2M and free cash flow to -$12.2M, backed by $140.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 27/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -2.53% and institutional whale pillar of 4/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $50.07 – $124.82 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), MNPR carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can MNPR sustain or expand its — operating margin and -17.4% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $46.8M and free cash flow of -$12.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is MNPR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

MNPR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Monopar Therapeutics Inc. (MNPR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MNPR Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MNPR Bull vs. Bear Conversation Board — What's Your Call at $66.28?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MNPR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on MNPR:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $83.68 (+19.0%)
📌 Pinned Debate

Cash rose from $45.8M to $61.8M across FY 2024 to FY 2025 while the Forensic Balance Sheet pillar scored 10 of 20 with a Debt/Equity of

Don't sleep on MNPR's setup in Health Care. Cash rose from $45.8M to $61.8M across FY 2024 to FY 2025 while the Forensic Balance Sheet pillar scored 10 of 20 with a Debt/Equity of 0.5.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (27/100) backs up the fundamental quality.

VolSurface_Trader 🐂 BULL

Both sides have a point here — MNPR's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $57.66 (-18.0%)
Spot @ $70.32

With zero reported revenue, negative ROIC of -17.4%, and a negative FCF yield of -2.53%, the Fundamental Cash Engine pillar scores only

Here is the bear case nobody on the bull side wants to address on MNPR: With zero reported revenue, negative ROIC of -17.4%, and a negative FCF yield of -2.53%, the Fundamental Cash Engine pillar scores only 4 of 20.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE